Description

Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2].—COVID-19-anti-virus–C32H55N9O10—-[1]Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94.|[2]Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427.–258818-34-7–725.83—-NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O–Infection; Inflammation/Immunology–10 mM in DMSO–Gap Junction Protein—-Cytoskeleton–Peptides